November 5, 2021
Daiichi Sankyo and UK partner AstraZeneca said on November 3 that European regulatory authorities have accepted for review an application seeking approval for Enhertu (trastuzumab deruxtecan) for the second-line treatment of HER2-positive gastric cancer. Enhertu, an HER2-targeting antibody drug conjugate...read more